Malvina Papanastasiou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Malvina Papanastasiou has a total of 598 co-authors. Here are the top co-authors by number of shared publications:
- Jacob D. Jaffe
Broad Institute of MIT and Harvard, Cambridge, USA
37 shared publications - Kornelia Polyak
Department of Medical Oncology, Dana-Farber Cancer Institute
36 shared publications - Franziska Michor
Department of Data Science, Dana-Farber Cancer Institute
35 shared publications - Alexander Meissner
Max Planck Institute for Molecular Genetics, Berlin, Germany
34 shared publications - Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
34 shared publications - Marco Seehawer
Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, USA
34 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program
ASXL1 mutations confer a poor prognosis in myeloid neoplasms, including in CALR-mutated myeloproliferative neoplasms (MPN). We generated Calr-Asxl1 co-mutant mice and found more severe thrombocytosis and increased splenomegaly, compared with Calr single-mutant animals. Calr-Asxl 1 co-mutant megakaryocytes displayed more pronounced morphological abnormalities and enhanced emperipolesis characteristic of inflammation. Concordant with this, a differentiation trajectory directly to megakaryocytes from hematopoietic stem cells (HSC) was more prominent in Calr-Asxl1 co-mutant mice. In this non-canonical trajectory, where megakaryocyte-biased HSCs directly differentiate into megakaryocyte progenitors, we found upregulation of Mef2c , a key transcriptional regulator of megakaryocyte lineage commitment. Mature Calr-Asxl1 co-mutant megakaryocytes displayed an enhanced proinflammatory transcriptional state, whereas the transcriptional signature of Calr-Asxl1 co-mutant HSCs was indicative of inflammation-resistance. Genotyping of transcriptomes (GoT) confirmed an activated megakaryocytic differentiation program in CALR-ASXL 1 co-mutant HSCs in primary human MPN bone marrow. These findings link the enhanced severity of CALR-ASXL1 co-mutant MPN to altered megakaryocyte differentiation and help explain some of the biological basis for the more severe MPN phenotype observed in patients.
- 29 October 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
Open AccessMutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program
ASXL1 mutations confer a poor prognosis in myeloid neoplasms, including in CALR-mutated myeloproliferative neoplasms (MPN). We generated Calr-Asxl1 co-mutant mice and found more severe thrombocytosis and increased splenomegaly, compared with Calr single-mutant animals. Calr-Asxl 1 co-mutant megakaryocytes displayed more pronounced morphological abnormalities and enhanced emperipolesis characteristic of inflammation. Concordant with this, a differentiation trajectory directly to megakaryocytes from hematopoietic stem cells (HSC) was more prominent in Calr-Asxl1 co-mutant mice. In this non-canonical trajectory, where megakaryocyte-biased HSCs directly differentiate into megakaryocyte progenitors, we found upregulation of Mef2c , a key transcriptional regulator of megakaryocyte lineage commitment. Mature Calr-Asxl1 co-mutant megakaryocytes displayed an enhanced proinflammatory transcriptional state, whereas the transcriptional signature of Calr-Asxl1 co-mutant HSCs was indicative of inflammation-resistance. Genotyping of transcriptomes (GoT) confirmed an activated megakaryocytic differentiation program in CALR-ASXL 1 co-mutant HSCs in primary human MPN bone marrow. These findings link the enhanced severity of CALR-ASXL1 co-mutant MPN to altered megakaryocyte differentiation and help explain some of the biological basis for the more severe MPN phenotype observed in patients.
- Open Access
Seed-Guided De Novo Design Expands the Structural Diversity of Antitoxin Protein Binders
De novo design of protein binders targeting extended, multi-site interaction surfaces remains difficult for current generative methods, which often produce limited structural diversity and predominantly helical topologies. Here, we advance diffusion-based binder design by guiding protein backbone generation through ″seeds,″ which are PDB-derived fragments selected for geometric complementarity to the target surface. To test this approach, we computationally generated seed-guided binders of the bacterial toxin RelE. RelB, the native antitoxin of RelE, engages two distinct interfaces with high surface complementarity, making it an appropriate test case. Seed-guided RFdiffusion produced backbones with substantially higher structural diversity and more target contacts than RFdiffusion alone. Experimental screening of 1,402 designs in a high-throughput bacterial survival assay identified multiple functional binders, including variants with nanomolar to low-micromolar affinity and one design with RelE neutralization comparable to RelB pep . Computational structure prediction and mutational analyses support that the designed interfaces rely on seed-derived contacts and adopt binding modes distinct from RelB. Molecular dynamics simulations and hydrogen-deuterium exchange experiments further suggest that one high-affinity design undergoes a conformational change upon binding. Notably, successful designs exhibited reduced cross-reactivity to RelE orthologs compared with RelB pep , suggesting that the extensive interfaces generated through seed-guided design can enable enhanced selectivity. These results establish motif scaffolding of surface-complementing seeds as an effective strategy for overcoming current limitations of de novo generative models, enabling the design of proteins that can engage challenging interface sites.
Open AccessSeed-Guided De Novo Design Expands the Structural Diversity of Antitoxin Protein Binders
De novo design of protein binders targeting extended, multi-site interaction surfaces remains difficult for current generative methods, which often produce limited structural diversity and predominantly helical topologies. Here, we advance diffusion-based binder design by guiding protein backbone generation through ″seeds,″ which are PDB-derived fragments selected for geometric complementarity to the target surface. To test this approach, we computationally generated seed-guided binders of the bacterial toxin RelE. RelB, the native antitoxin of RelE, engages two distinct interfaces with high surface complementarity, making it an appropriate test case. Seed-guided RFdiffusion produced backbones with substantially higher structural diversity and more target contacts than RFdiffusion alone. Experimental screening of 1,402 designs in a high-throughput bacterial survival assay identified multiple functional binders, including variants with nanomolar to low-micromolar affinity and one design with RelE neutralization comparable to RelB pep . Computational structure prediction and mutational analyses support that the designed interfaces rely on seed-derived contacts and adopt binding modes distinct from RelB. Molecular dynamics simulations and hydrogen-deuterium exchange experiments further suggest that one high-affinity design undergoes a conformational change upon binding. Notably, successful designs exhibited reduced cross-reactivity to RelE orthologs compared with RelB pep , suggesting that the extensive interfaces generated through seed-guided design can enable enhanced selectivity. These results establish motif scaffolding of surface-complementing seeds as an effective strategy for overcoming current limitations of de novo generative models, enabling the design of proteins that can engage challenging interface sites.
- Top Cited Papers
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eaeb3627
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
Mammalian switch/sucrose nonfermenting (mSWI/SNF) chromatin remodeling complexes modulate DNA accessibility and gene expression; however, their genomic targeting mechanisms remain incompletely understood. Here, we identify SWIFT [SWI/SNF immunoglobulin fold (Ig-fold) for transcription factor interactions], a conserved transcription factor (TF) binding domain on the SMARCD subunits. SWIFT is necessary and sufficient for direct engagement with the transactivation domain of the PU.1 TF. A single amino acid mutation disrupts PU.1-mSWI/SNF binding, impairs complex targeting, and attenuates oncogenic transcription and proliferation in PU.1-dependent human cancer cells. Dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF and poisons TF-“addicted” cancer cells. Finally, TFs across diverse families interact with SMARCD paralog-specific SWIFT domains. These results define a major mechanism of cell type– and disease-specific mSWI/SNF chromatin targeting and inform approaches toward therapeutic modulation.
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eaeb3627
Top Cited PapersA SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
Mammalian switch/sucrose nonfermenting (mSWI/SNF) chromatin remodeling complexes modulate DNA accessibility and gene expression; however, their genomic targeting mechanisms remain incompletely understood. Here, we identify SWIFT [SWI/SNF immunoglobulin fold (Ig-fold) for transcription factor interactions], a conserved transcription factor (TF) binding domain on the SMARCD subunits. SWIFT is necessary and sufficient for direct engagement with the transactivation domain of the PU.1 TF. A single amino acid mutation disrupts PU.1-mSWI/SNF binding, impairs complex targeting, and attenuates oncogenic transcription and proliferation in PU.1-dependent human cancer cells. Dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF and poisons TF-“addicted” cancer cells. Finally, TFs across diverse families interact with SMARCD paralog-specific SWIFT domains. These results define a major mechanism of cell type– and disease-specific mSWI/SNF chromatin targeting and inform approaches toward therapeutic modulation.
- Open Access
- 29 January 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (3) , 101519
Nanoscaled, Fully Automated Hydrogen/Deuterium Exchange for Analysis of Macromolecular Assemblies Reaching the MDa Scale
- 29 January 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (3) , 101519
Open AccessNanoscaled, Fully Automated Hydrogen/Deuterium Exchange for Analysis of Macromolecular Assemblies Reaching the MDa Scale
- Open Access
- 12 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11100
Mass spectrometry-based profiling of single-cell histone post-translational modifications to dissect chromatin heterogeneity
Single-cell proteomics confidently quantifies cellular heterogeneity, however quantification of post-translational modifications, such as those deposited on histone proteins, remains elusive. Here, we develop a robust mass spectrometry-based method for the unbiased analysis of single-cell histone post-translational modifications (sc-hPTM). sc-hPTM identifies both single- and combinatorial histone post-translational modifications (67 peptidoforms in total), which includes nearly all frequently studied histone post-translational modifications with comparable reproducibility to traditional bulk experiments. As a proof of concept, we treat cells with sodium butyrate, a histone deacetylase inhibitor, and demonstrate that our method can i) distinguish between treated and untreated cells, ii) identify sub-populations of cells with heterogeneous response to the treatment, and iii) reveal differential co-regulation of histone post-translational modifications in the context of drug treatment. The sc-hPTM method enables comprehensive investigation of chromatin heterogeneity at single-cell resolution and provides a further understanding of the histone code.
- 12 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11100
Open AccessMass spectrometry-based profiling of single-cell histone post-translational modifications to dissect chromatin heterogeneity
Single-cell proteomics confidently quantifies cellular heterogeneity, however quantification of post-translational modifications, such as those deposited on histone proteins, remains elusive. Here, we develop a robust mass spectrometry-based method for the unbiased analysis of single-cell histone post-translational modifications (sc-hPTM). sc-hPTM identifies both single- and combinatorial histone post-translational modifications (67 peptidoforms in total), which includes nearly all frequently studied histone post-translational modifications with comparable reproducibility to traditional bulk experiments. As a proof of concept, we treat cells with sodium butyrate, a histone deacetylase inhibitor, and demonstrate that our method can i) distinguish between treated and untreated cells, ii) identify sub-populations of cells with heterogeneous response to the treatment, and iii) reveal differential co-regulation of histone post-translational modifications in the context of drug treatment. The sc-hPTM method enables comprehensive investigation of chromatin heterogeneity at single-cell resolution and provides a further understanding of the histone code.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States